Publications by authors named "Nerea Roch"
Allogeneic hematopoietic stem cell transplant (HCT) recipients are at high risk of severe COVID-19 despite vaccination. Little is known about cellular response to SARS-CoV-2 vaccine in this population, especially in recently transplanted patients (RTP). In this single-center study we examined cellular and humoral response to the mRNA-1273 (Spikevax®) vaccine in recently transplanted patients (RTP, n = 49), and compared them to long-term transplanted patients (LTTP, n = 19) and healthy controls (n = 20) at three different timepoints: one and three months after the second dose (T1 and T2, respectively, 28 days apart), and one month after the third dose (T3).
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the safety and adverse events (AEs) related to the mRNA-1273 SARS-CoV-2 vaccine in patients who have undergone allogeneic hematopoietic stem cell transplants (HCT) within the last two years.
- A total of 54 HCT recipients were monitored, revealing that the incidence and severity of AEs were comparable to those seen in the general population, with injection site pain being the most common issue.
- The findings also indicated that female patients and those more recently transplanted were more likely to experience AEs, while the patients' perception of COVID-19 risk decreased over time.